期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

索拉非尼片治疗晚期肾癌显效1例

下载PDF
导出
摘要 现将我院收治的应用索拉非尼治疗晚期肾癌1例予以报道 1病例资料男性，77岁，2002年7月体检发现右肾占位，给予行右肾癌根治切术，术后病理：右肾透明细胞癌，
作者 黄志有
机构地区 温州市中医院肿瘤科
出处 《中国中医药现代远程教育》 2010年第6期113-113,共1页 Chinese Medicine Modern Distance Education of China
关键词 索拉非尼 晚期肾癌 中医肿瘤学 医案
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1Cohen HT, McGovem FJ. Renal-Cell Carcinoma. N Engl J Med. 2005 Dec 8; 353(23): 2477-90.
  • 2Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy[J]. J Clin Oncol.1995 Mar; 13(3): 6 88-96.
  • 3Motzer R.I, Bacik J, Murphy BA, et al. Interferon-alfa as a comparati ve treatment for clinical trials of new therapies against advanced ren al cell carcinoma[J]. J Clin Oncol, 2002;20(1):289-296.
  • 4盛锡楠,李峻岭,郭军,赵小慧,朱军,储大同.重组人源化白细胞介素2治疗转移性肾癌的临床研究[J].中华肿瘤杂志,2008,30(2):129-133. 被引量：18
  • 5斯璐,廉红云,盛锡楠,迟志宏,袁香庆,崔传亮,郭军.rhIL-2治疗肾癌肺转移的Ⅲ期临床研究中期总结[J].肿瘤学杂志,2008,14(5):366-369. 被引量：8
  • 6Wilhelm SM, Carter C, Tang L, et al.BAY 43-9006 exhibits broad sp ectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angi ogenesis[J]. Cancer Rcs 2004;64:7099-109.

二级参考文献20

  • 1Tourani JM, Lucas V, Mayeur D, et al. Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma: results of a multieenter SCAPP1 trial. Ann Oneol, 1996, 7:525-528.
  • 2Donskov F, yon der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol, 2006, 24 : 1997-2005.
  • 3Cohen HT, McGovem FJ. Renal-ceU carcinoma. N Engl J Med, 2005, 353:2477-2490.
  • 4Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer, 1997, 80: 1198- 1220.
  • 5Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356:125- 134.
  • 6Motzer R J, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356 : 115-124.
  • 7Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am, 2000, 6 : S55-57.
  • 8Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 1995, 13:688-696.
  • 9Geertsen PF, Gore ME, Negrier S, et al. Safety and efficacy of subcutaneous and continuous intravenous infusion aIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer, 2004, 90: 1156-1162.
  • 10Rouvière O,Bouvier R,Négrier S,et al.Nonmetastatic renal-cell carcinoma:is it really possible to define rational guidelines for post treatment follow-up?[J].Nat Clin Pract Oncol,2006,3(4):200-213.

共引文献21

中国中医药现代远程教育
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部